The rise in BioSante Pharmaceuticals (BPAX -13.2%) is attributable to frenzied day trading of a new momo favorite, according to biotech analyst Adam Feuerstein. He also remains underwhelmed with the FDA approval the company landed for its testosterone-boosting gel given that 5 competing products are already in the market. Despite today's selloff, BPAX is on a +67.6% YTD bender.
The rise in BioSante Pharmaceuticals (BPAX -13.2%) is attributable to frenzied day trading of a...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs